| Name | Title | Contact Details |
|---|
The Wildcat team consists of successful entrepreneurs turned investors. Over the years, we have observed that most startups can build a product but many falter in the go-to-market phase, exposing themselves to lower valuations, significant financing risks, and suboptimal outcomes. In fact, industry data shows that more than 75% of startups fail to gain traction and never return capital invested. In stark contrast to these industry statistics, 70% of the companies we have backed have been successful. To achieve these results, we have developed a unique investment and operating framework generated from our collective experience; it is called the Traction Gap. We use the Traction Gap framework - terminology, strategies and tactics – to work with teams to help them successfully transition from product development into company scaling.
Legal & General Investment Management America, Inc. (LGIMA) is a registered investment advisor specializing in designing and managing investment solutions across active fixed income, index strategies, multi-asset, liability driven investment, and sustainable investment strategies for the US institutional market. With over $210 billion in assets under management as of September 30, 2019, LGIMA is a wholly-owned subsidiary of Legal & General Investment Management US (Holdings) Inc., which is in turn, wholly owned by Legal & General Investment Management (Holdings) Ltd. (LGIM(H)). LGIM(H) also owns our affiliates Legal & General Investment Management Ltd. and LGIM International Ltd. Legal & General`s worldwide assets under management are over $1 trillion as of December 31, 2018.
Arcadia Management is a Boston, MA-based company in the Financial Services sector.
Arista Wealth Management is a Las Vegas, NV-based company in the Financial Services sector.
RA Capital Management (“RA Capital”) is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization. RA Capital`s scientifically trained research team is intensely data driven in its continual effort to identify early breakthroughs and originate conviction in new ideas. The team`s understanding of industry best practices is derived from an extensive collection of case studies documenting the impact of clinical trial design, partnership structures, public market dynamics, and many other factors on valuation and business viability.